Prognostic implication of high risk human papillomavirus E6 and E7 mRNA in patients with intraepithelial lesions of the cervix in relationship to age

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 2, 2011, Pages 461-470

  Frega, A ^a   Lorenzon, L ^b   Giovagnoli, M R ^c   De Sanctis, L ^a   Fabiano, V ^c   Lukic, A ^a   Moscarini, M ^a   Torrisi, M R ^c   French, Deborah ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cervical cytology; E6; E7; High risk HPV; LSIL

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROTEIN E6; PROTEIN E7; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOLOGY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; ADOLESCENT; COMPARATIVE STUDY; GENOTYPE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE E6; HUMAN PAPILLOMAVIRUS TYPE E7; HUMAN TISSUE; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; PROTEIN EXPRESSION; RISK FACTOR; RNA ANALYSIS; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; VIRUS DETECTION; ANALYTICAL EQUIPMENT; CHI SQUARE DISTRIBUTION; EVALUATION; GENETICS; ITALY; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; PATHOLOGY; PREDICTIVE VALUE; RISK ASSESSMENT; TIME; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; FEMALE; HUMANS; ITALY; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REAGENT KITS, DIAGNOSTIC; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; RNA, VIRAL; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIRAL ENVELOPE PROTEINS; YOUNG ADULT;

EID: 80051728737     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400219     Document Type: Article

References (25)

1. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995; 141:680-9.
2. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the papanicolau test in screening for and follow-up of cervical cytology abnormalities: a systematic review. Ann Intern Med 2000; 132:810-9. (Pubitemid 30317797)
3. Stanley M. Pathology and epidemiology of HPV infection in females. Gynaecol Oncol 2010; 117:5-10.
4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370:890-07.
5. Munoz N, Bosch FX, De Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. The International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27. (Pubitemid 36159887)
6. Sundström K, Eloranta S, Sparén P, et al. Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix Cancer Epidemiol Biomarkers Prev 2010; 19:2469-78.
7. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-8. (Pubitemid 28135669)
8. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364:1678-83. (Pubitemid 39458143)
9. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini F. Efficacy of human papilloma virus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11:249-57.
10. Lytwin A, Sellors JW, Mahony JB, et al. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation. Arch Pathol Lab Med 2003; 127:1169-175. (Pubitemid 37093266)
11. Naucler P, Ryd W, Törnberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Can Inst 2009; 101:88-99.
12. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 2007; 212:356-67. (Pubitemid 47099012)
13. Hudson JB, Bedell MA, McCance DJ, Laiminis LA. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 1990; 64:519-26. (Pubitemid 20032661)
14. Varnai AD, Bollmann M, Bankfalvi A, Speich N, Schmitt C, Griefingholt H, Kovács K, Klozoris C, Bollmann R. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep 2008; 19:457-65. (Pubitemid 351176108)
15. Von Knebel Doeberitz M, Syrjanen KJ. Molecular markers: how to apply in practice. Gynecol Oncol 2006; 103:18-20. (Pubitemid 44374722)
16. Cushieri K, Wentzensen N. HPV mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Can Epidemiol Biomark Prev 2008; 17:2536-45.
17. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92:276-84. (Pubitemid 32225381)
18. Hariri J, Oster A. The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol 2007; 26:223-8. (Pubitemid 46986053)
19. Wentzensen N, Bergeron C, Cas F, Vinokurova S, Von Knebel Doeberitz M. Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer 2007; 111:58-66. (Pubitemid 46281086)
20. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004; 73:65-70. (Pubitemid 38429149)
21. Ratnam S, Coutlee F, Fontaine D, et al. Clinical performance of the PreTec HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 Test for identification of women at risk of cervical cancer. J Clin Microbiol 2010; 48:2779-785.
22. Sorbye SW, Fismen S, Gutterberg T, Mortensen ES. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. Plos One 2010; 5:12724.
23. Cattani P, Zannini GF, Ricci C, et al. Clinical performance of Human Papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol 2009; 47:3895-901.
24. Molden T, Nygard JF, Kraus I, et al. Predicting CIN2 + when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005; 114:973-76.
25. Molden T, Kraus I, Karlsen F, et al. Comparison of Human Papillomavirus messanger RNA and DNA detection: a cross-sectional study of 4,136 women>30 years of age with a 2-years follow-up of high-grade squamous intraepithelial lesion. Can Epidemiol Biomark Prev 2005; 14:367-72. (Pubitemid 40270098)